Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment
EXCLI Journal · 22.09.2026 · 25 · 1488-1512
DOI: 10.17179/excli2026-9310 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 22.09.2026. Verfasst von Kyung-Soo Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in prevalence worldwide. Pathogenesis of MASLD has been considerably heterogenous. Increased hepatic de novo lipogenesis, adipose tissue dysfunction, genetic predisposition, epigenetic mechanism, and other related factors have been associated with the development and progression of MASLD. Patients with MASLD are at high risk of not only adverse liver-related outcomes, including hepatocellular carcinoma, but also cardiometabolic disease including type 2 diabetes mellitus. Weight loss is the cornerstone of therapy among the various treatments for MASLD to decrease hepatic fat accumulation and delay the progression of inflammation and fibrosis. Resmetirom and semaglutide are approved for the treatment of metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis, and many drugs are under investigation. Careful attention should be paid to the screening of MASLD, and concerted efforts should be made to manage it appropriately.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Zitieren
APA
Kim, K. S., Lim, S., & Park, C. Y. (2026). Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment. EXCLI Journal, 25, 1488-1512. https://doi.org/10.17179/excli2026-9310
Vancouver
Kim KS, Lim S, Park CY. Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment. EXCLI Journal. 2026;25:1488-1512. doi:10.17179/excli2026-9310
BibTeX
@article{Kim2026,
author = {Kim, Kyung-Soo and Lim, Soo and Park, Cheol-Young},
title = {Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment},
journal = {EXCLI Journal},
year = {2026},
volume = {25},
pages = {1488--1512},
doi = {10.17179/excli2026-9310}
}
EUVIMED